HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medical Marijuana Inc. Stands By EU CBD Approval As Media Reports Call Into Question Firm's Claims

Executive Summary

Medical Marijuana Inc. says claims that it has lost its licence to sell CBD as a food supplement in Bulgaria are incorrect. The firm tells HBW Insight it has in fact been granted additional approval to export CBD products from Bulgaria to Russia.

You may also be interested in...

Sweden's Hemp-Derived CBD Market Under Threat Following Supreme Court Ruling

CBD from industrial hemp that contains any trace of THC, however small, is a controlled drug, Sweden's Supreme Court has ruled. The country has moved to close a legal loophole that was being taken advantage of by retailers to avoid prosecution for selling CBD oils as supplements.

Medical Marijuana Inc. Claims First CBD Supplement Approval In EU

Bulgaria has granted US-based Medical Marijuana Inc. the right to sell CBD as a supplement in a first for an EU country. The move, which will see CBD regulated as a traditional food, puts Bulgaria directly at odds with the European Commission, which recently classified the cannabis plant extract as a novel food.

With CBD Poised To Become A Novel Food In Europe, Industry Must Think Ahead To Gain Advantage

Europe's dynamic CBD market could soon see tighter regulation, after the European Commission (EC) last month added the ingredient to its Novel Food Catalogue. Regulatory expert Janet Worrell argues that the time is now for CBD industry players to act to get ahead of this potentially transformative development. 


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts